ATRA News - Candlesense

Atara Biotherapeutics Announces Changes to Its Board of Directors

(NASDAQ:ATRA) THOUSAND OAKS, Calif--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl...

Board

6 days ago

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to dev...

What are the company's plans for international expansion or regulatory filings outside the U.S.? What are the potential reimbursement and payer landscape for Tabelecel in the U.S. and internationally? What is the timeline and expected cost for the next Phase 2/3 trial for Tabelecel?

Earnings

29 days ago